Matches in Wikidata for { <http://www.wikidata.org/entity/Q70488840> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- Q70488840 description "article scientifique publié en 1984" @default.
- Q70488840 description "artículu científicu espublizáu en xunetu de 1984" @default.
- Q70488840 description "im Juli 1984 veröffentlichter wissenschaftlicher Artikel" @default.
- Q70488840 description "scientific article published on 01 July 1984" @default.
- Q70488840 description "wetenschappelijk artikel" @default.
- Q70488840 description "наукова стаття, опублікована в липні 1984" @default.
- Q70488840 name "Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study" @default.
- Q70488840 name "Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study" @default.
- Q70488840 type Item @default.
- Q70488840 label "Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study" @default.
- Q70488840 label "Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study" @default.
- Q70488840 prefLabel "Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study" @default.
- Q70488840 prefLabel "Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study" @default.
- Q70488840 P1433 Q70488840-99E9843C-06A9-4AE3-BD05-F50F776FB12A @default.
- Q70488840 P1476 Q70488840-19FF355F-4978-44EC-AAA4-023545358EE7 @default.
- Q70488840 P2093 Q70488840-174B961F-A363-41B7-B849-EC6FF87EB556 @default.
- Q70488840 P2093 Q70488840-3757B660-4A15-4F70-A648-40ECD2D7138C @default.
- Q70488840 P2093 Q70488840-57F910EA-F813-467B-8381-3694CFEB78D8 @default.
- Q70488840 P2093 Q70488840-749BCE48-FAD3-4E81-B7AC-8EA3A383A8B4 @default.
- Q70488840 P2093 Q70488840-854EC8C6-E950-4620-98D2-753672091F03 @default.
- Q70488840 P2093 Q70488840-DB5A5B2D-7769-4F74-B51D-3B96457C0BC6 @default.
- Q70488840 P2093 Q70488840-E9E0A8FB-76EF-4562-B898-6E2F3BB16F81 @default.
- Q70488840 P304 Q70488840-663A3268-A8A2-42B1-89CE-6BDD9A6CE77E @default.
- Q70488840 P31 Q70488840-11027BE9-98B8-4B70-9993-78FED23CDF19 @default.
- Q70488840 P433 Q70488840-C223DAF3-F676-4C42-9341-6DAC88D78299 @default.
- Q70488840 P478 Q70488840-D9358442-13C6-4092-B6BB-495A67A6AA2A @default.
- Q70488840 P50 Q70488840-cbb52514-4a49-ecfc-dcf0-0d488b1536ee @default.
- Q70488840 P577 Q70488840-A43D37A1-23C4-420E-9F1D-0AD4DB0333B3 @default.
- Q70488840 P698 Q70488840-2F2922EB-D486-4878-B2CF-EBE8C24D3795 @default.
- Q70488840 P921 Q70488840-7070460E-F60F-40E9-B1A7-57E9BA634885 @default.
- Q70488840 P921 Q70488840-F111ED71-8783-4020-9D50-B29EA9DEDA07 @default.
- Q70488840 P698 6430559 @default.
- Q70488840 P1433 Q27710285 @default.
- Q70488840 P1476 "Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study" @default.
- Q70488840 P2093 "Costanzi JJ" @default.
- Q70488840 P2093 "Crawford ED" @default.
- Q70488840 P2093 "Frank J" @default.
- Q70488840 P2093 "Grozea PN" @default.
- Q70488840 P2093 "Oishi N" @default.
- Q70488840 P2093 "Stephens RL" @default.
- Q70488840 P2093 "Stuckey WJ" @default.
- Q70488840 P304 "1025-1026" @default.
- Q70488840 P31 Q13442814 @default.
- Q70488840 P433 "7-8" @default.
- Q70488840 P478 "68" @default.
- Q70488840 P50 Q89036040 @default.
- Q70488840 P577 "1984-07-01T00:00:00Z" @default.
- Q70488840 P698 "6430559" @default.
- Q70488840 P921 Q18556149 @default.
- Q70488840 P921 Q18936 @default.